{"id":36595,"date":"2024-07-24T20:01:12","date_gmt":"2024-07-24T12:01:12","guid":{"rendered":"https:\/\/docquity.com\/?post_type=articles&p=36595"},"modified":"2025-02-11T13:40:49","modified_gmt":"2025-02-11T05:40:49","slug":"diem-tin-hoi-nghi-ada-2024-thu-nghiem-flow-loi-ich-tren-than-va-tim-mach-cua-semaglutide-o-benh-nhan-dai-thao-duong-type-2-co-nguy-co-cao","status":"publish","type":"articles","link":"https:\/\/docquity.com\/vi\/articles\/diem-tin-hoi-nghi-ada-2024-thu-nghiem-flow-loi-ich-tren-than-va-tim-mach-cua-semaglutide-o-benh-nhan-dai-thao-duong-type-2-co-nguy-co-cao\/","title":{"rendered":"\u0110i\u1ec3m tin H\u1ed9i ngh\u1ecb ADA 2024: Th\u1eed nghi\u1ec7m FLOW \u2013 L\u1ee3i \u00edch tr\u00ean th\u1eadn v\u00e0 tim m\u1ea1ch c\u1ee7a semaglutide \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 c\u00f3 nguy c\u01a1 cao"},"content":{"rendered":"\n

H\u1ed9i ngh\u1ecb khoa h\u1ecdc th\u01b0\u1eddng ni\u00ean l\u1ea7n th\u1ee9 84 c\u1ee7a Hi\u1ec7p h\u1ed9i \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng Hoa K\u1ef3 (ADA) n\u0103m 2024 \u0111\u00e3 di\u1ec5n ra t\u1eeb ng\u00e0y 21 \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 6 n\u0103m 2024 t\u1ea1i Orlando, Florida, Hoa K\u1ef3. H\u1ed9i ngh\u1ecb ADA l\u1ea7n th\u1ee9 84 c\u1eadp nh\u1eadt nh\u1eefng ti\u1ebfn b\u1ed9 m\u1edbi nh\u1ea5t trong nghi\u00ean c\u1ee9u v\u00e0 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng, th\u1ea3o lu\u1eadn v\u1ec1 c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ti\u00ean ti\u1ebfn v\u00e0 chia s\u1ebb kinh nghi\u1ec7m l\u00e2m s\u00e0ng v\u1edbi \u0111\u1ed3ng nghi\u1ec7p t\u1eeb kh\u1eafp n\u01a1i tr\u00ean th\u1ebf gi\u1edbi. Ch\u1ee7 \u0111\u1ec1 tr\u1ecdng t\u00e2m c\u1ee7a h\u1ed9i ngh\u1ecb ADA n\u0103m 2024 bao g\u1ed3m c\u00e1c l\u0129nh v\u1ef1c nh\u01b0 \u1ee9ng d\u1ee5ng c\u00f4ng ngh\u1ec7 v\u00e0 tr\u00ed tu\u1ec7 nh\u00e2n t\u1ea1o trong qu\u1ea3n l\u00fd v\u00e0 \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng, c\u00e1c lo\u1ea1i thu\u1ed1c m\u1edbi trong \u0111i\u1ec1u tr\u1ecb b\u00e9o ph\u00ec v\u00e0 \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng, c\u00f9ng nhi\u1ec1u v\u1ea5n \u0111\u1ec1 kh\u00e1c li\u00ean quan \u0111\u1ebfn s\u1ee9c kh\u1ecfe v\u00e0 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng.<\/p>\n\n\n\n

Nh\u1eb1m gi\u00fap qu\u00fd v\u1ecb \u0111\u1ed3ng nghi\u1ec7p n\u1eafm b\u1eaft nh\u1eefng nghi\u00ean c\u1ee9u v\u00e0 th\u00f4ng tin \u0111\u00e1ng ch\u00fa \u00fd nh\u1ea5t trong h\u1ed9i ngh\u1ecb, \u0110\u1ed9i ng\u0169 Docquity h\u00e2n h\u1ea1nh gi\u1edbi thi\u1ec7u chu\u1ed7i c\u00e1c b\u00e0i vi\u1ebft \u201c\u0110i\u1ec3m tin H\u1ed9i ngh\u1ecb ADA 2024\u201d, b\u00e0n lu\u1eadn v\u1ec1 k\u1ebft qu\u1ea3 c\u1ee7a c\u00e1c nghi\u00ean c\u1ee9u SURMOUNT \u2013 OSA, SELECT, STEP-HFpEF v\u00e0 STEP-HFpEF-DM, FLOW, INHALE-3 v\u00e0 ATTEMPT.<\/p>\n\n\n\n

B\u00e0i vi\u1ebft n\u00e0y \u0111\u1ec1 c\u1eadp \u0111\u1ebfn th\u1eed nghi\u1ec7m FLOW, b\u00e0n lu\u1eadn v\u1ec1 l\u1ee3i \u00edch tr\u00ean th\u1eadn v\u00e0 tim m\u1ea1ch c\u1ee7a semaglutide \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 c\u00f3 nguy c\u01a1 cao [1]<\/sup>.<\/p>\n\n\n\n

Q\u00fay v\u1ecb \u0111\u1ed3ng nghi\u1ec7m c\u00f3 th\u1ec3 tham kh\u1ea3o c\u00e1c b\u00e0i vi\u1ebft \u0111\u1ec1 c\u1eadp \u0111\u1ebfn nghi\u00ean c\u1ee9u SURMOUNT-OSA qua \u0111\u01b0\u1eddng link: https:\/\/docquity.app.link\/TOg8RagOqLb<\/a><\/em><\/p>\n\n\n\n

S\u01a0 L\u01af\u1ee2C V\u1ec0 SEMAGLUTIDE<\/strong><\/h2>\n\n\n\n

Semaglutide l\u00e0 m\u1ed9t ch\u1ea5t ch\u1ee7 v\u1eadn th\u1ee5 th\u1ec3 GLP-1 (glucagon-like peptide-1) \u0111\u01b0\u1ee3c ph\u00e1t tri\u1ec3n b\u1edfi Novo Nordisk. GLP-1 l\u00e0 m\u1ed9t hormone incretin \u0111\u01b0\u1ee3c ti\u1ebft ra t\u1eeb ru\u1ed9t non sau b\u1eefa \u0103n, c\u00f3 vai tr\u00f2 quan tr\u1ecdng trong vi\u1ec7c \u0111i\u1ec1u ch\u1ec9nh l\u01b0\u1ee3ng \u0111\u01b0\u1eddng huy\u1ebft. Semaglutide ho\u1ea1t \u0111\u1ed9ng b\u1eb1ng c\u00e1ch t\u0103ng c\u01b0\u1eddng ti\u1ebft insulin v\u00e0 \u1ee9c ch\u1ebf ti\u1ebft glucagon khi m\u1ee9c \u0111\u01b0\u1eddng huy\u1ebft t\u0103ng, \u0111\u1ed3ng th\u1eddi l\u00e0m ch\u1eadm qu\u00e1 tr\u00ecnh l\u00e0m r\u1ed7ng d\u1ea1 d\u00e0y, gi\u00fap duy tr\u00ec c\u1ea3m gi\u00e1c no l\u00e2u h\u01a1n [1]<\/sup>.<\/p>\n\n\n\n

Semaglutide \u0111\u01b0\u1ee3c ch\u1ea5p thu\u1eadn cho ch\u1ec9 \u0111\u1ecbnh \u0111i\u1ec1u tr\u1ecb \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2. Ngo\u00e0i ra, semaglutide c\u0169ng \u0111\u01b0\u1ee3c nghi\u00ean c\u1ee9u, ph\u00e1t tri\u1ec3n v\u00e0 \u0111\u00e3 \u0111\u01b0\u1ee3c ch\u1ea5p thu\u1eadn cho ch\u1ec9 \u0111\u1ecbnh \u0111i\u1ec1u tr\u1ecb b\u00e9o ph\u00ec. Nhi\u1ec1u b\u1eb1ng ch\u1ee9ng \u0111\u00e3 \u1ee7ng h\u1ed9 hi\u1ec7u l\u1ef1c gi\u1ea3m c\u00e2n c\u1ee7a semaglutide [2 \u2013 4]. Kh\u00f4ng nh\u1eefng v\u1eady, semaglutide c\u00f2n cho th\u1ea5y l\u1ee3i \u00edch quan tr\u1ecdng kh\u00e1c tr\u00ean s\u1ee9c kh\u1ecfe tim m\u1ea1ch. Nghi\u00ean c\u1ee9u SUSTAIN-6 \u0111\u00e3 cho th\u1ea5y semaglutide l\u00e0m gi\u1ea3m nguy c\u01a1 c\u00e1c bi\u1ebfn c\u1ed1 tim m\u1ea1ch l\u1edbn (MACE) bao g\u1ed3m nh\u1ed3i m\u00e1u c\u01a1 tim, \u0111\u1ed9t qu\u1ef5 v\u00e0 t\u1eed vong do tim m\u1ea1ch [5]<\/sup>.<\/p>\n\n\n\n

TH\u1eec NGHI\u1ec6M FLOW<\/strong><\/h2>\n\n\n\n

B\u1ec7nh nh\u00e2n m\u1eafc \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 v\u00e0 b\u1ec7nh th\u1eadn m\u1ea1n c\u00f3 nguy c\u01a1 cao m\u1eafc c\u00e1c bi\u1ebfn ch\u1ee9ng tr\u00ean th\u1eadn v\u00e0 bi\u1ebfn ch\u1ee9ng tim m\u1ea1ch. C\u00e1c ch\u1ea5t ch\u1ee7 v\u1eadn th\u1ee5 th\u1ec3 glucagon-like peptide-1 (GLP-1 RA) v\u00e0 ch\u1ea5t \u1ee9c ch\u1ebf k\u00eanh \u0111\u1ed3ng v\u1eadn chuy\u1ec3n natri-glucose-2 (SGLT2i) \u0111\u1ed9c l\u1eadp l\u00e0m gi\u1ea3m c\u00e1c bi\u1ebfn c\u1ed1 tim m\u1ea1ch v\u00e0 th\u1eadn. Tuy nhi\u00ean, t\u00e1c \u0111\u1ed9ng c\u1ee7a vi\u1ec7c k\u1ebft h\u1ee3p c\u1ea3 hai lo\u1ea1i thu\u1ed1c n\u00e0y v\u1eabn ch\u01b0a r\u00f5 r\u00e0ng. SGLT2i c\u00f3 hi\u1ec7u qu\u1ea3 trong ph\u00f2ng ng\u1eeba suy th\u1eadn, suy tim v\u00e0 c\u00e1c k\u1ebft qu\u1ea3 tim m\u1ea1ch. GLP-1 RA bao g\u1ed3m semaglutide, c\u0169ng mang l\u1ea1i l\u1ee3i \u00edch \u0111\u00e1ng k\u1ec3 cho c\u00e1c k\u1ebft c\u1ee5c tim m\u1ea1ch v\u00e0 b\u1ec7nh th\u1eadn m\u1ea1n. C\u01a1 ch\u1ebf ho\u1ea1t \u0111\u1ed9ng ph\u00e2n t\u1eed c\u1ee7a SGLT2i v\u00e0 GLP-1 RA tr\u00ean h\u1ec7 tim m\u1ea1ch v\u00e0 th\u1eadn c\u00f3 th\u1ec3 b\u1ed5 sung cho nhau v\u00e0 \u0111\u1ed9c l\u1eadp v\u1edbi vi\u1ec7c gi\u1ea3m \u0111\u01b0\u1eddng huy\u1ebft. Do v\u1eady, gi\u1ea3 thuy\u1ebft cho r\u1eb1ng vi\u1ec7c ph\u1ed1i h\u1ee3p 2 nh\u00f3m thu\u1ed1c n\u00e0y c\u00f3 th\u1ec3 c\u1ea3i thi\u1ec7n k\u1ebft c\u1ee5c tim m\u1ea1ch v\u00e0 th\u1eadn c\u1ee7a b\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c \u0111\u1eb7t ra [6]<\/sup>.<\/p>\n\n\n\n

Hi\u1ec7n ch\u01b0a c\u00f3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng tr\u1ef1c ti\u1ebfp n\u00e0o \u0111\u01b0\u1ee3c ti\u1ebfn h\u00e0nh v\u1ec1 hi\u1ec7u l\u1ef1c c\u1ee7a ph\u1ed1i h\u1ee3p GLP-1 RA v\u00e0 SGLT2i \u0111\u1ed1i v\u1edbi c\u00e1c k\u1ebft c\u1ee5c tr\u00ean th\u1eadn v\u00e0 tim m\u1ea1ch \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 m\u1eafc k\u00e8m b\u1ec7nh th\u1eadn m\u1ea1n. Do \u0111\u00f3, th\u1eed nghi\u1ec7m FLOW \u0111\u00e3 \u0111\u01b0\u1ee3c ti\u1ebfn h\u00e0nh \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh l\u1ee3i \u00edch ti\u1ec1m n\u0103ng v\u00e0 s\u1ef1 an to\u00e0n c\u1ee7a semaglutide \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 m\u1eafc k\u00e8m b\u1ec7nh th\u1eadn m\u1ea1n \u0111ang \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb ho\u1eb7c kh\u00f4ng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i [6]<\/sup>.<\/p>\n\n\n\n

K\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m FLOW<\/strong><\/h2>\n\n\n\n

C\u00f3 t\u1ed5ng c\u1ed9ng 3,533 b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 m\u1eafc k\u00e8m b\u1ec7nh th\u1eadn m\u1ea1n tham gia th\u1eed nghi\u1ec7m FLOW. B\u1ec7nh nh\u00e2n tham gia nghi\u00ean c\u1ee9u \u0111\u01b0\u1ee3c ph\u00e2n t\u1ea7ng d\u1ef1a tr\u00ean vi\u1ec7c \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i (N = 550) ho\u1eb7c kh\u00f4ng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i (N = 2,983). Sau \u0111\u00f3, b\u1ec7nh nh\u00e2n \u1edf 2 ph\u00e2n nh\u00f3m n\u00e0y ti\u1ebfp t\u1ee5c \u0111\u01b0\u1ee3c chia ng\u1eabu nhi\u00ean v\u00e0o 2 nh\u00f3m \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb v\u1edbi (i) semaglutide li\u1ec1u 1.0 mg\/tu\u1ea7n ho\u1eb7c (ii) gi\u1ea3 d\u01b0\u1ee3c. K\u1ebft c\u1ee5c ch\u00ednh l\u00e0 bi\u1ebfn c\u1ed1 g\u1ed9p bao g\u1ed3m suy th\u1eadn (\u0111\u01b0\u1ee3c \u0111\u1ecbnh ngh\u0129a b\u1eb1ng \u0111\u1ed9 l\u1ecdc c\u1ea7u th\u1eadn \u01b0\u1edbc t\u00ednh \u2013 eGFR gi\u1ea3m \u226550%), t\u1eed vong do th\u1eadn ho\u1eb7c t\u1eed vong do tim m\u1ea1ch [6]<\/sup>.<\/p>\n\n\n\n

B\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb b\u1eb1ng semaglutide c\u00f3 t\u1ef7 l\u1ec7 bi\u1ebfn c\u1ed1 g\u1ed9p th\u1ea5p h\u01a1n 24% so v\u1edbi gi\u1ea3 d\u01b0\u1ee3c. C\u1ee5 th\u1ec3, \u1edf ph\u00e2n nh\u00f3m b\u1ec7nh nh\u00e2n \u0111ang \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i, t\u1ef7 l\u1ec7 bi\u1ebfn c\u1ed1 g\u1ed9p \u1edf nh\u00f3m semaglutide l\u00e0 41\/277 v\u00e0 \u1edf nh\u00f3m gi\u1ea3 d\u01b0\u1ee3c l\u00e0 38\/273 (RR 1.07; CI 95%: 0.69, 1.67; p<\/em> = 0.755). \u0110\u1ed1i v\u1edbi ph\u00e2n nh\u00f3m b\u1ec7nh nh\u00e2n kh\u00f4ng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i, t\u1ef7 l\u1ec7 bi\u1ebfn c\u1ed1 g\u1ed9p \u1edf nh\u00f3m semaglutide v\u00e0 gi\u1ea3 d\u01b0\u1ee3c l\u1ea7n l\u01b0\u01a1t l\u00e0 290\/1,490 v\u00e0 372\/1,493 (RR 0.73; CI 95% 0.63, 0.85; p<\/em> < 0.001; p interaction<\/em> 0.109) [6]<\/sup>.<\/p>\n\n\n\n

\u0110\u1ed1i v\u1edbi t\u1ed1c \u0111\u1ed9 gi\u1ea3m c\u1ee7a eGFR (ml.min-1<\/sup>\/1.73 m2<\/sup>\/n\u0103m), \u0111\u1ed9 d\u1ed1c c\u1ee7a eGFR t\u1ed5ng c\u1ed9ng c\u1ee7a b\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi semaglutide \u1edf 2 ph\u00e2n nh\u00f3m \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i v\u00e0 kh\u00f4ng \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i l\u1ea7n l\u01b0\u1ee3t l\u00e0 0.75 (\u22120.01, 1.5) v\u00e0 1.25 (0.91, 1.58) (p interaction<\/em> 0.237). K\u1ebft qu\u1ea3 v\u1ec1 t\u1ef7 l\u1ec7 MACE v\u00e0 t\u1eed vong do m\u1ecdi nguy\u00ean nh\u00e2n c\u0169ng t\u01b0\u01a1ng t\u1ef1, cho th\u1ea5y semaglutide c\u00f3 l\u1ee3i \u00edch b\u1ea5t k\u1ec3 b\u1ec7nh nh\u00e2n c\u00f3 \u0111ang \u0111\u01b0\u1ee3c \u0111i\u1ec1u tr\u1ecb v\u1edbi SGLT2i hay kh\u00f4ng (p interaction<\/em> l\u1ea7n l\u01b0\u1ee3t l\u00e0 0.741 v\u00e0 0.901) [6]<\/sup>.<\/p>\n\n\n\n

K\u1ebeT LU\u1eacN<\/strong><\/h2>\n\n\n\n

Th\u1eed nghi\u1ec7m FLOW cho th\u1ea5y semaglutide l\u00e0m ch\u1eadm ti\u1ebfn tri\u1ec3n b\u1ec7nh th\u1eadn v\u00e0 c\u1ea3i thi\u1ec7n k\u1ebft c\u1ee5c tr\u00ean th\u1eadn v\u00e0 t\u1eed vong do tim m\u1ea1ch \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2 m\u1eafc k\u00e8m b\u1ec7nh th\u1eadn m\u1ea1n [7]<\/sup>.<\/p>\n\n\n\n

C\u00f3 nhi\u1ec1u b\u1ec7nh nh\u00e2n m\u1eafc b\u1ec7nh th\u1eadn m\u1ea1n t\u1eed vong do nguy\u00ean nh\u00e2n tim m\u1ea1ch. Do v\u1eady v\u1eady, c\u1ea7n ph\u1ea3i t\u1eadp trung gi\u1ea3m nguy c\u01a1 to\u00e0n di\u1ec7n cho b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng m\u1eafc k\u00e8m b\u1ec7nh th\u1eadn m\u1ea1n, kh\u00f4ng ch\u1ec9 t\u1eadp trung v\u00e0o nguy c\u01a1 tr\u00ean th\u1eadn m\u00e0 c\u00f2n t\u1eadp trung v\u00e0o v\u00e0o k\u1ebft qu\u1ea3 tim m\u1ea1ch v\u00e0 t\u1eed vong [7]<\/sup>.<\/p>\n\n\n\n

Semaglutide l\u00e0m gi\u1ea3m 24% nguy c\u01a1 bi\u1ebfn c\u1ed1 g\u1ed9p, bao g\u1ed3m suy th\u1eadn, t\u1eed vong do nguy\u00ean nh\u00e2n tim m\u1ea1ch v\u00e0 th\u1eadn. Ngo\u00e0i ra, semaglutide c\u00f2n c\u00f3 th\u1ec3 l\u00e0m ch\u1eadm t\u1ed1c \u0111\u1ed9 suy gi\u1ea3m eGFR, gi\u1ea3m 18% MACE v\u00e0 gi\u1ea3m 20% nguy c\u01a1 t\u1eed vong do m\u1ecdi nguy\u00ean nh\u00e2n. Th\u1eed nghi\u1ec7m FLOW \u0111\u00e3 \u0111\u01b0\u1ee3c ng\u01b0ng s\u1edbm h\u01a1n d\u1ef1 ki\u1ebfn do hi\u1ec7u qu\u1ea3 r\u00f5 r\u00e0ng c\u1ee7a semaglutide [7]<\/sup>.<\/p>\n\n\n\n

Hi\u1ec7n nay c\u00f3 4 nh\u00f3m thu\u1ed1c \u0111i\u1ec1u tr\u1ecb ch\u00ednh cho b\u1ec7nh nh\u00e2n \u0111\u1ed3ng m\u1eafc b\u1ec7nh th\u1eadn m\u1ea1n v\u00e0 \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng type 2, bao g\u1ed3m ch\u1ea5t \u1ee9c ch\u1ebf men chuy\u1ec3n angiotensin (ACEI) ho\u1eb7c thu\u1ed1c ch\u1eb9n th\u1ee5 th\u1ec3 angiotensin (ARB), SGLT2i, thu\u1ed1c \u0111\u1ed1i kh\u00e1ng mineralocorticoid kh\u00f4ng steroid finerenone. V\u1edbi k\u1ebft c\u1ee7a c\u1ee7a th\u1eed nghi\u1ec7m FLOW, semaglutide cho th\u1ea5y ti\u1ec1m n\u0103ng tr\u1edf th\u00e0nh m\u1ed9t l\u1ef1a ch\u1ecdn cho nh\u00f3m b\u1ec7nh nh\u00e2n n\u00e0y.<\/p>\n\n\n\n

\n\n\n\n

T\u00c0I LI\u1ec6U THAM KH\u1ea2O<\/strong><\/h3>\n\n\n\n
    \n
  1. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017. FDA. Accessed date 17 Jul. URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf<\/li>\n\n\n\n
  2. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056\/NEJMoa2032183.<\/li>\n\n\n\n
  3. Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016\/S0140-6736(21)00213-0.<\/li>\n\n\n\n
  4. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001\/jama.2021.1831.<\/li>\n\n\n\n
  5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056\/NEJMoa1607141.<\/li>\n\n\n\n
  6. Mann, J.F.E., Rossing, P., Bakris, G. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med (2024). https:\/\/doi.org\/10.1038\/s41591-024-03133-0<\/li>\n\n\n\n
  7. ADA Meeting News. FLOW trial demonstrates kidney, cardiovascular benefits of semaglutide in high-risk patients with type 2 diabetes. Accessed date 19 Jul 2024. URL: https:\/\/www.adameetingnews.org\/flow-trial-demonstrates-kidney-cardiovascular-benefits-of-semaglutide-in-high-risk-patients-with-type-2-diabetes\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    H\u1ed9i ngh\u1ecb khoa h\u1ecdc th\u01b0\u1eddng ni\u00ean l\u1ea7n th\u1ee9 84 c\u1ee7a Hi\u1ec7p h\u1ed9i \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng Hoa K\u1ef3 (ADA) n\u0103m 2024 \u0111\u00e3 di\u1ec5n ra t\u1eeb ng\u00e0y 21 \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 6 n\u0103m 2024 t\u1ea1i Orlando, Florida, Hoa K\u1ef3.<\/p>\n","protected":false},"author":123,"featured_media":36610,"comment_status":"closed","ping_status":"closed","template":"","meta":{"content-type":"","inline_featured_image":false,"site-sidebar-layout":"default","site-content-layout":"default","ast-global-header-display":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":""},"articles_categories":[1370],"articles_tags":[],"articles_topics":[1436],"articles_languages":[1375],"articles_filters":[],"class_list":["post-36595","articles","type-articles","status-publish","has-post-thumbnail","hentry","articles_categories-medical-content-vi","articles_languages-vietnamese-vi"],"_links":{"self":[{"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles\/36595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles"}],"about":[{"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/types\/articles"}],"author":[{"embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/comments?post=36595"}],"version-history":[{"count":0,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles\/36595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/media\/36610"}],"wp:attachment":[{"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/media?parent=36595"}],"wp:term":[{"taxonomy":"articles_categories","embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles_categories?post=36595"},{"taxonomy":"articles_tags","embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles_tags?post=36595"},{"taxonomy":"articles_topics","embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles_topics?post=36595"},{"taxonomy":"articles_languages","embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles_languages?post=36595"},{"taxonomy":"articles_filters","embeddable":true,"href":"https:\/\/docquity.com\/vi\/wp-json\/wp\/v2\/articles_filters?post=36595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}